Table 4.
C‐index and continuous net reclassification index for all‐cause death using classical risk markers plus biomarkers (continuous) in those with complete data (n = 1853, n events 769)
| Biomarker | C‐index (95% CI) P‐value | Net reclassification index | |||
|---|---|---|---|---|---|
| Classical markers | Classical + NT‐proBNP | Group | Classical markers | Classical + NT‐proBNP | |
| Comparator | 0.669 | 0.713 | – | – | – |
| (0.651–0.688) | (0.694–0.732) | ||||
| NT‐proBNP | 0.713 | – | Cases | 23.7% | – |
| (0.694–0.732) | Non‐case | 22.6% | – | ||
| P = 0.002 | Overall | 46.3%, P < 0.001 | – | ||
| Troponin T | 0.699 | 0.721 | Cases | 14.8% | 6.3% |
| (0.680–0.718) | (0.704–0.738) | Non‐case | 31.7% | 20.6% | |
| P = 0.002 | P = 0.196 | Overall | 46.5%, P < 0.001 | 26.9%, P = 0.01 | |
| MR‐proADM | 0.687 | 0.714 | Cases | 18.0% | 9.5% |
| (0.668–0.706) | (0.695–0.731) | Non‐case | 24.6% | 6.5% | |
| P = 0.002 | P = 0.890 | Overall | 42.6%, P < 0.001 | 16%, P = 0.13 | |
| Copeptin | 0.676 | 0.715 | Cases | 12.8% | 11.2% |
| (0.658–0.695) | (0.697–0.732) | Non‐case | 6.5% | –2.5% | |
| P = 0.014 | P = 0.740 | Overall | 19.3%, P = 0.036 | 8.7%, P = 0.346 | |
| Cystatin C | 0.679 | 0.715 | Cases | 18.7% | 10.7% |
| (0.661–0.698) | (0.698–0.732) | Non‐case | 4.5% | –10.6% | |
| P = 0.002 | P = 0.726 | Overall | 23.2%, P = 0.006 | 0.2%, P = 0.635 | |
| CRP | 0.673 | 0.714 | Cases | 7.3% | 5.7% |
| (0.654–0.692) | (0.696–0.732) | Non‐case | 6.5% | –5.5% | |
| P = 0.160 | P = 0.778 | Overall | 13.8%, P = 0.1 | 0.1%, P = 0.783 | |
| All biomarkers | 0.719 | 0.719 | Cases | 24.1% | 11.7% |
| (0.701–0.737) | (0.701–0.737) | Non‐case | 36.7% | 15.6% | |
| P = 0.002 | P = 0.306 | Overall | 60.7%, P < 0.001 | 27.2%, P < 0.001 | |
CI, confidence interval; CRP, C‐reactive protein; MR‐proADM, mid‐regional pro‐adrenomedullin; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.
Model: adjusting for region, age, sex, race, body mass index, smoking, systolic and diastolic blood pressure, diabetes, chronic obstructive pulmonary disease, New York Heart Association class, left ventricular ejection fraction, time since diagnosis, angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker use, beta‐blocker use, creatinine, heart failure hospitalization within last 6 months, heart failure aetiology, stroke, atrial fibrillation/flutter, heart rate.